Solventum (SOLV)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$91.69-0.81%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · SOLV
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $92 SOLV trades at 13× p/e, below its 20× p/e peer median, but our blended $87 fair value sits below the price. We hold it with medium confidence: quality doesn't explain valuation multiples in this sub-industry, so the peer comparison is a weak guide. Analysts target $43–$113. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $95.00 | — | — | Analyst | high |
| graham number | 12M | $66.52 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $70.33 | 10.1 | 9.61 | TTM | high |
| Peer P/E | 12M | $144.62 | 20.4 | 7.10 | TTM | high |
| Peer P/S | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$43.00 – $113.00 (median $95.00) · 10 analysts · as of 2026-08-06
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $91.69 |
| 1.9 |
| 47.95 |
| TTM |
| high |
| PEG | 12M | $40.69 | 5.7 | 7.10 | TTM | high |
| residual income | 12M | $46.53 | — | — | TTM | high |
| Own P/E history | 12M | $88.68 | 12.5 | 7.10 | TTM | high |
| triangulated | 12M | $157.34 | 20.4 | 7.72 | Triangulated | high |
| Peer P/E | 3Y | $155.90 | 20.4 | 7.65 | Analyst | medium |
| Peer P/S | 3Y | $98.64 | 1.9 | 51.58 | guidance | medium |
| PEG | 3Y | $43.87 | 5.7 | 7.65 | Analyst | medium |
| Own P/E history | 3Y | $95.60 | 12.5 | 7.65 | Analyst | medium |
| Peer P/E | 5Y | $164.59 | 20.4 | 8.08 | Analyst | high |
| Peer P/S | 5Y | $104.14 | 1.9 | 54.46 | guidance | high |
| PEG | 5Y | $46.31 | 5.7 | 8.08 | Analyst | high |
| Own P/E history | 5Y | $100.93 | 12.5 | 8.08 | Analyst | high |